Latest News for: chronic obstructive pulmonary disease

Edit

Chronic Obstructive Pulmonary Disease Treatment Devices Market Insights, Competitive Landscape, And Market Forecast 2024-2032

MENA FN 08 Aug 2025
(MENAFN - GlobeNewsWire - Nasdaq) The Chronic Obstructive Pulmonary Disease (COPD) Treatment Devices Market is set to grow at a CAGR of 6.35% from 2025 to 2032. This surge is driven by rising COPD ... .
Edit

Global Chronic Obstructive Pulmonary Disease Treatment Devices Market to Witness Growth at a CAGR of ...

Nasdaq Globe Newswire 05 Aug 2025
The market for chronic obstructive pulmonary disease treatment devices is projected to witness substantial growth, fueled by several major drivers ... The market for chronic obstructive pulmonary disease ...
Edit

Genentech Provides Update on Astegolimab in Chronic Obstructive Pulmonary Disease

Hastings Tribune 21 Jul 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jul 21, 2025-- ... .
Edit

Genentech Provides Update on Astegolimab in Chronic Obstructive Pulmonary Disease (Roche Holding AG)

Public Technologies 21 Jul 2025
). The text version of this document is not available ... Disclaimer ... (noodl. 125465107) .
Edit

Genentech Provides Update on Astegolimab in Chronic Obstructive Pulmonary Disease (Genentech Inc)

Public Technologies 21 Jul 2025
... (n=1,375) trials investigating astegolimab compared to placebo, on top of standard of care maintenance therapy in people with moderate to very severe chronic obstructive pulmonary disease (COPD).
Edit

Fosun Pharma’s Self-Developed New Drug XH-S004 for the Treatment of Chronic Obstructive Pulmonary Disease Enters Phase 1b Clinical Trial (Shanghai Fosun Pharmaceutical (Group) Co Ltd)

Public Technologies 17 Jul 2025
XH-S004 is a small molecule oral DPP-1 inhibitor independently developed by Fosun Pharma, which is intended to be used for the treatment of chronic obstructive pulmonary disease (COPD), non-cystic fibrosis bronchiectasis and others.
Edit

“If they had checked my lungs sooner”: Revaz Vachnadze’s story of living with chronic obstructive pulmonary disease is a call to action (WHO - World Health Organization Regional Office for Europe)

Public Technologies 12 Jun 2025
) Revaz Vachnadze from Georgia chain smoked for many years ... What they did not check at the time were his lungs ... [...]. This is an abstract of the document ... Disclaimer.
Edit

Chronic Obstructive Pulmonary Disease Market was valued at USD 16,075 million in 2023 and is ...

GetNews 11 Jun 2025
Chronic Obstructive Pulmonary Disease Epidemiology Segmentation in the 7MM Total Prevalence of Chronic Obstructive Pulmonary Disease Prevalent Cases of Chronic Obstructive Pulmonary Disease by ...
Edit

Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials

Nasdaq Globe Newswire 30 May 2025
AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically meaningful benefit ... .
Edit

Chronic Obstructive Pulmonary Disease Market Analysis and Sales Forecasts to 2033

Nasdaq Globe Newswire 29 May 2025
Explore the future of the COPD market with our comprehensive report covering 68 geographic markets ... .
Edit

Global Chronic Obstructive Pulmonary Disease (COPD) Market Set to Surpass USD 33.19 Billion by 2033 Amid Rising Disease Burden and Therapeutic Demand | FMI

Pharmiweb 28 May 2025
The global chronic obstructive pulmonary disease market is poised for substantial growth, with projections indicating a valuation of USD 21.58 billion in 2023 ... The Chronic Obstructive Pulmonary Disease (COPD) market is segmented as follows.
Edit

FDA Approves Nucala for Chronic Obstructive Pulmonary Disease

US News 24 May 2025
Approval is for adult patients with COPD with eosinophilic inflammation ... .
Edit

Nucala (mepolizumab) approved by US FDA for use in adults with chronic obstructive pulmonary disease (COPD)

Business Wire 23 May 2025
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE.
Edit

Nucala (mepolizumab) approved by US FDA for use in adults with chronic obstructive pulmonary disease (COPD) (GSK plc)

Public Technologies 23 May 2025
The condition of patients ranged in severity from moderate to very severe, or stages 2-4 as assessed by the medically recognised scale of Global Initiative for Chronic Obstructive Lung Disease (GOLD).
Edit

Nucala (mepolizumab) approved by US FDA for use in adults with chronic obstructive pulmonary disease (COPD) (Form 6-K) (GSK plc)

Public Technologies 23 May 2025
Nucala (mepolizumab) approved by US FDA for use in adults with chronic obstructive pulmonary disease (COPD) ... Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease ... disease (COPD) in 2019.

Article Search

tools
×
×
×
×